FDA Accepts Ascendis Pharmas Supplemental Biologics License Application for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

ASND Stock  USD 129.87  0.77  0.59%   
About 55% of Ascendis Pharma's investor base is interested to short. The analysis of the overall investor sentiment regarding Ascendis Pharma AS suggests that many traders are impartial. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.
  
PDUFA goal date is July 27, 2025COPENHAGEN, Denmark, Dec. 12, 2024 -- Ascendis Pharma AS today announced that the U.S. Food Drug Administration has accepted for review its supplemental Biologics License Application in adult growth hormone deficiency for TransCon hGH . The FDA set a Prescription Drug User Fee Act goal date of July 27, 2025. This marks another step toward

Read at finance.yahoo.com
Yahoo News
  

Ascendis Pharma AS Current Investor Sentiment

Panic Vs Confidence

45

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ascendis Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ascendis Pharma AS.

Ascendis Pharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Ascendis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ascendis Pharma AS Historical Investor Sentiment

Investor biases related to Ascendis Pharma's public news can be used to forecast risks associated with an investment in Ascendis. The trend in average sentiment can be used to explain how an investor holding Ascendis can time the market purely based on public headlines and social activities around Ascendis Pharma AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ascendis Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ascendis Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ascendis Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Ascendis Pharma.

Ascendis Pharma Fundamental Analysis

We analyze Ascendis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Ascendis Pharma is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Ascendis Pharma AS Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ascendis Pharma stock to make a market-neutral strategy. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics with similar companies.

Peers

Ascendis Pharma Related Equities

REPLReplimune   2.70   
0%
41.0%
APLSApellis Pharmaceuticals   1.37   
0%
20.0%
MDGLMadrigal Pharmaceuticals   0.67   
0%
10.0%
BPMCBlueprint Medicines   0.66   
0%
10.0%
ACLXArcellx   0.46   
0%
6.0%
UTHRUnited Therapeutics   0.06   
0%
1.0%
NUVLNuvalent   0.05   
0%
1.0%
DAWNDay One   0.47   
7.0%
0%
AKROAkero Therapeutics   0.48   
7.0%
0%
BGNEBeiGene   0.51   
7.0%
0%
ETNB89bio   2.04   
31.0%
0%
STOKStoke Therapeutics   2.11   
32.0%
0%
CRNXCrinetics Pharmaceuticals   3.52   
53.0%
0%
PLRXPliant Therapeutics   3.97   
60.0%
0%
VTYXVentyx Biosciences   6.56   
99.0%
0%
AMLXAmylyx Pharmaceuticals   6.58   
100.0%
0%

Complementary Tools for Ascendis Stock analysis

When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency